Novel NMDA Antagonists: Replacement of the Pyridinium Ring of 6,11-Ethanobenzo[b]quinolizinium Cations with Heteroisoquinolinium Cations
摘要:
Replacement of the pyridinium ring of 6,11-ethanobenzo[b]quinolizinium cations with thiazolium (4a and 4b) and N-methylimidazolium (4c and 4d) resulted in equipotent compounds in the [H-3]TCP binding assay. The corresponding N-methyl-1,2,4-triazolium analogs were less potent in this assay. The thiazolium derivative 4b, with a K-i = 2.9 nM, is being evaluated as a possible neuroprotective N-methyl-D-aspartic acid (NMDA) antagonist.
Substituted heterocyclylisoquinolinium salts and compositions and
申请人:Sterling Winthrop Inc.
公开号:US05604224A1
公开(公告)日:1997-02-18
Substitutued heterocyclylisoquinolinium salts, pharmaceutical compositions containing them and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.
替代杂环异喹啉盐,含有它们的制药组合物以及利用它们治疗或预防神经退行性疾病或神经毒性损伤的方法。
Substituted heterocyclylisoquinolinium salts and compositions and methods of usethereof
申请人:STERLING WINTHROP INC.
公开号:EP0647641A1
公开(公告)日:1995-04-12
Substitutued heterocyclylisoquinolinium salts of Formula
pharmaceutical compositions containing them and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.
Substituted heterocyclylisoquinolinium salts and compositions and method
申请人:Sterling Winthrop Inc.
公开号:US05569655A1
公开(公告)日:1996-10-29
Substitutued heterocyclylisoquinolinium salts, pharmaceutical compositions containing them and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.